10x Genomics (MEX:TXG) Float Percentage Of Total Shares Outstanding : 60.31% (As of Jul. 04, 2025)

View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 10x Genomics's float shares is 74.25 Mil. 10x Genomics's total shares outstanding is 123.13 Mil. 10x Genomics's float percentage of total shares outstanding is 60.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 10x Genomics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 10x Genomics's Institutional Ownership is 53.06%.

10x Genomics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

10x Genomics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	74.25	/	123.13
	=	60.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

TXG:USA 0A88:UK 1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).